They Just Don't Get...
Health Care: Drugs
AspenBio Pharma Inc. (APPY: NASDAQ)
$0.49 0.01 | 2.51%
06/04/12 - 10:18 AM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 281.60K | 370.23K | 504.82K | 821.44K |
| Cost of Sales | -411.99K | -65.67K | 31.13K | 262.10K |
| Gross Operating Profit | 693.59K | 435.90K | 473.69K | 559.34K |
| Selling, General, and Administrative Expenses | 5.58M | 7.51M | 6.63M | 4.43M |
| Research & Development | 5.67M | 6.02M | 8.71M | 6.03M |
| Operating Income before D & A (EBITDA) | -10.55M | -13.09M | -14.87M | -9.90M |
| Depreciation & Amortization | 428.34K | 423.77K | 174.26K | 319.58K |
| Interest Income | 16.42K | 61.70K | 189.43K | 746.09K |
| Other Income - Net | 942.90K | 313.02K | -461.68K | 133.07K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -10.02M | -13.14M | -15.32M | -9.34M |
| Interest Expense | 196.93K | 194.48K | 200.14K | 228.55K |
| Pre-Tax Income | -10.21M | -13.34M | -15.52M | -9.57M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -10.21M | -13.34M | -15.52M | -9.57M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -10.21M | -13.34M | -15.52M | -9.57M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -10.21M | -13.34M | -15.52M | -9.57M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-10.21M | -13.34M | -15.52M | -9.57M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -10.21M | -13.34M | -15.52M | -9.57M |
| Basic EPS from Continuing Ops. | -1.27 | -1.70 | -2.35 | -1.55 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.27 | -1.70 | -2.35 | -1.55 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.27 | -1.70 | -2.35 | -1.55 |
| Basic Normalized Net Income/Share | -1.27 | -1.70 | -2.35 | -1.55 |
| EPS fr Continuing Ops. | -1.27 | -1.70 | -2.35 | -1.55 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.27 | -1.70 | -2.35 | -1.55 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.27 | -1.70 | -2.35 | -1.55 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.27 | -1.70 | -2.35 | -1.55 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with APPY
- Portfolio NameUser Type
- UserSUPRATRADE-2709091838
- UserBrahmsian's Debt/Equity Por...
- UserBrahmsian's Financially Sou...
- Userdan vosika Portfolio 1
- Usergame on
- Userdreamerl3oi Portfolio 1
- Useremannn Portfolio 1
- UserKBEE Portfolio 1
- UserMoney and Suits Portfolio 1
- UserFly Me To The Moon Monster ...
Latest APPY Headlines from TheStreet
- Biotech Sector Weekly Rewind 11.13.10 | 07:11 am
- Vantage Drilling, First M&F: Volume Movers 07.20.10 | 07:07 am
- AspenBio Finds Fault Afar for Failure 07.20.10 | 06:07 am
- Biotech Stock Mailbag: Spectrum Pharma 06.18.10 | 07:06 am
- Hellenic Telecom, AspenBio Pharma: Midday Volume Plays 06.07.10 | 12:06 pm
- Stock Offerings: Navios Maritime 04.30.10 | 11:04 am
- Biotech Stock Mailbag: AspenBio 04.30.10 | 06:04 am
- ClickSoftware, AspenBio: Early Volume Plays 12.29.09 | 07:12 am
- AspenBio Pharma Prices Public Offering 10.07.09 | 08:10 am
- Biotech News Roundup: Aspen, AMAG, Vertex 08.17.09 | 12:08 pm
Press Releases for APPY
- AspenBio Appoints Diagnostics Industry Veteran Don Hurd As Senior Vice President And Chief Commercial Officer - Business Wire 05.24.12 | 09:05 am
- AspenBio Pharma’s Clinical Study Suggests One-Third Of CT Scans Used To Assess Pediatric And Adolescent Patients At Low Risk For Acute Appendicitis Could Potentially Be Avoided - Business Wire 04.18.12 | 09:04 am
- Results Of 503-Patient Clinical Study Of AspenBio Pharma’s AppyScore™ Blood Test Show 97% Negative Predictive Value For Absence Of Acute Appendicitis In Children And Adolescents Presenting With Abdominal Pain - Business Wire 03.16.12 | 02:03 pm
- Study Demonstrates AspenBio Pharma’s AppyScore Multi-Marker Blood Test Highly Predictive For Absence Of Acute Appendicitis In Children With Abdominal Pain - Business Wire 02.28.12 | 09:02 am
- Rigrodsky & Long, P.A. Announces Class Action Lawsuit Against AspenBio Pharma, Inc. - Business Wire 10.07.10 | 04:10 pm
- The Law Office Of Robbins Umeda LLP Announces The Filing Of A Class Action Suit Against AspenBio Pharma, Inc. - Business Wire 10.07.10 | 04:10 pm
- Investor Notice: The Rosen Law Firm Announces Investigation Of Shareholder Securities Claims Against AspenBio Pharma, Inc. --- APPY - Business Wire 09.03.10 | 08:09 pm
Partner Headlines for APPY
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- AspenBio Pharma Reports AppyScore(TM) ELISA-Based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-Based Test - Benzinga 07.19.10 | 04:07 pm
- AspenBio Pharma Shares Plummet on Drug Application Delay - Fox Business 06.07.10 | 04:06 pm
- 4 Small Cap Biotechs To Keep an Eye On - Seeking Alpha 05.26.10 | 04:05 pm
- Thursday Outlook: What, Me Worry? - Seeking Alpha 05.13.10 | 10:05 am
- Biotech CROs Take Center Stage in Recent Deals - Seeking Alpha 05.02.10 | 05:05 am
- Takeover Speculation Swarms at AspenBio Pharma - SeekingAlpha.com 04.26.10 | 03:04 am
- Preview of AspenBio's Potentially Blockbuster Clinical Trials - SeekingAlpha.com 04.25.10 | 08:04 am
- Friday Options Recap - SeekingAlpha.com 04.23.10 | 03:04 pm
- Will AspenBio Pharma Follow in Dendreon and Human Genome Sciences' Footsteps? - SeekingAlpha.com 04.22.10 | 04:04 am
